🦊/Investors

Whiz Partners Inc.

Private equity

Tokyo · Seed–Late Stage · 6 people tracked

Find your way into Whiz Partners Inc.

72 people in our graph share verified history with the Whiz Partners Inc. team — schools, employers, funds. One of them is your warm intro.

Shinobu Suzukiunlockedknows Takahiro Suzuki · together at RIKEN (overlapped)
×9knows the team · via California State University - East Bay
knows the team · via Whiz Partners Inc.
knows the team · via RIKEN
Fox Verdict
Sign up to see your fit

Investment thesis

Whiz Partners positions itself as an independent investment firm that combines dialogue-driven investment in listed small- and mid-cap companies (via PIPEs using convertible bonds and warrants with a VC-style hands-on approach) with private equity that actively shapes industry structure. It avoids hostile activism and passive portfolio investing, instead engaging deeply from company creation through management participation, as seen in the Takeda carve-out AxceleadT and the Japan-U.S. joint venture ARCALIS for domestic mRNA medicine production. Its focus areas center on healthcare, AI, and digital transformation, extending to defense, semiconductors, tourism, regional revitalization, education, and culture, with an emphasis on ethical conduct, compliance, and reproducible investment performance.

Source: firm website, verified Aug 7, 2026.

Stage
Seed–Late Stage
Check
$500K – $5M
HQ
Tokyo, JP
Instruments
Equity · Debt
Founded
2010
Tracked investments
2

Team · 6 people

from the firm's website & public directories
藤澤 朋行· 代表者 (Representative Director)

Co-representative of Whiz Partners.

Takahiro Suzuki· Directorin
Yuki Hasegawa· Head of Healthcare Investmentin

What they invest in

from 1 of 2 portfolio companies

AI & Machine Learning ×1Biotech ×1Healthtech ×1

HQs:Japan×1

Investments · 2 tracked

founders shown can be your intro path
ARCALISarcalis.co.jp

A US-Japan joint venture established in 2021 between Axcelead and US-based Arcturus Therapeutics for domestic mRNA drug/vaccine manufacturing, with sites in Minamisoma (Fukushima) and Kashiwanoha (Chiba).

Axceleadaxcelead-hd.com

Axcelead is a healthcare platform company with drug discovery as its core business, supporting pharmaceutical research for biotech ventures, pharmaceutical companies, and academic institutions.

AI & Machine LearningBiotechHealthtechTokyo, JP

池浦 義典(代表取締役社長兼執行役員CEO (Representative Director, President and Executive Officer CEO))前川 裕貴(代表取締役兼執行役員CFO (Representative Director and Executive Officer CFO))

Frequently asked questions

What stage does Whiz Partners Inc. invest at?
Whiz Partners Inc. invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is Whiz Partners Inc.'s typical check size?
Whiz Partners Inc. typically writes checks of $500K – $5M.
What sectors does Whiz Partners Inc. focus on?
Whiz Partners Inc. focuses on AI & Machine Learning, Biotech, Cleantech, Consumer, Data & Infrastructure, Defense Tech, EdTech, Enterprise Software, Hardware, Healthtech, Media & Entertainment, Medical Devices, New Materials, SaaS, Semiconductors, Travel & Hospitality.
Where is Whiz Partners Inc. located?
Whiz Partners Inc. is headquartered in Tokyo, JP.

Images

Whiz Partners Inc. photo

Similar investors

Featured in lists